- Home
- RMCO vs APLM Comparison
RMCO vs APLM Comparison
Compare RMCO & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- APLM
- Stock Information
- Founded
- RMCO 2021
- APLM 2016
- Country
- RMCO United States
- APLM United States
- Employees
- RMCO N/A
- APLM N/A
- Industry
- RMCO Multi-Sector Companies
- APLM Blank Checks
- Sector
- RMCO Miscellaneous
- APLM Finance
- Exchange
- RMCO Nasdaq
- APLM Nasdaq
- Market Cap
- RMCO 14.8M
- APLM 15.6M
- IPO Year
- RMCO N/A
- APLM N/A
- Fundamental
- Price
- RMCO $1.18
- APLM $9.75
- Analyst Decision
- RMCO
- APLM Strong Buy
- Analyst Count
- RMCO 0
- APLM 2
- Target Price
- RMCO N/A
- APLM $425.00
- AVG Volume (30 Days)
- RMCO 39.4K
- APLM 102.2K
- Earning Date
- RMCO 01-24-2025
- APLM 02-15-2025
- Dividend Yield
- RMCO N/A
- APLM N/A
- EPS Growth
- RMCO N/A
- APLM N/A
- EPS
- RMCO N/A
- APLM N/A
- Revenue
- RMCO $568,896.00
- APLM $2,101,000.00
- Revenue This Year
- RMCO N/A
- APLM N/A
- Revenue Next Year
- RMCO N/A
- APLM N/A
- P/E Ratio
- RMCO N/A
- APLM N/A
- Revenue Growth
- RMCO 21.05
- APLM 70.54
- 52 Week Low
- RMCO $0.70
- APLM $6.50
- 52 Week High
- RMCO $4.75
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- RMCO 61.39
- APLM 50.39
- Support Level
- RMCO $0.96
- APLM $7.23
- Resistance Level
- RMCO $1.28
- APLM $8.88
- Average True Range (ATR)
- RMCO 0.11
- APLM 1.37
- MACD
- RMCO 0.02
- APLM 0.21
- Stochastic Oscillator
- RMCO 73.68
- APLM 57.91
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.